IPA revealed PARP1/LMP1 targets were largely involved in metabolism and signaling, with two clusters emerging from gene function analysis (Fig 1D). In addition, disease or function analysis identified cancer, proliferation of lymphatic system, and proliferation of lymphocytes as LMP1/PARP1 targets that were decreased following olaparib treatment (Fig 1E). The gene discussed is PDLIM7; the disease is cancer.